Thank you, Mr. Chair.
I want to start with the motion I put on notice a few weeks ago. I think everyone agrees it's time to come back to that very important motion.
After that, I will let the Liberals have the floor because they indicated that they were going to seek unanimous consent to withdraw their amendment. The idea is to then move that the committee invite the pharmaceutical company representatives to appear at a special meeting. They will have a chance to make their case as to why the contracts should stay confidential and why we, as parliamentarians, should not be allowed to review the contracts in camera. Keep in mind that the motion already includes safeguards to not only keep the contracts confidential, but also steer clear of any intellectual property-related issues. I want to make something crystal clear: the purchase agreements with the pharmaceutical companies do not contain any intellectual property information about vaccine manufacturing whatsoever. It's important to set the record straight.
I also want to set the record straight about something else. A number of countries have disclosed their purchase agreements. Just so everyone knows, I repeat: those agreements have been disclosed elsewhere in the world.
I will leave it there, so my fellow member can have the floor.